Kyntra Bio
KYNB
146 hedge funds and large institutions have $518M invested in Kyntra Bio in 2016 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 60 increasing their positions, 28 reducing their positions, and 15 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 28
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
9% more funds holding
Funds holding: 134 → 146 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
26% less capital invested
Capital invested by funds: $699M → $518M (-$181M)
36% less call options, than puts
Call options by funds: $974K | Put options by funds: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.22M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$4.42M |
| 3 |
Millennium Management
New York
|
+$4M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$3.32M |
| 5 |
NC
Nexthera Capital
New York
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$50.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$12.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.26M |
| 4 |
VOAM
Vertex One Asset Management
Vancouver,
British Columbia, Canada
|
-$4.21M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.75M |
KYNB Hedge Fund Activity: Q2 2016 in Review
146 of the 3,755 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2016, worth a combined $518M — down 26% from $699M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KYNB positions and 15 closed out — a net gain of 13 holders — while 60 added to existing stakes and 28 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.22M. The largest seller was Visium Asset Management, exiting entirely with an estimated $50.3M sold.
- 146 institutional investors held Kyntra Bio (KYNB) as of Q2 2016, up from 134 in Q1 2016.
- Funds reported $518M of Kyntra Bio stock for Q2 2016, down 26% quarter-over-quarter.
- 28 funds opened new Kyntra Bio positions in Q2 2016 and 15 closed out, a net change of +13 holders.
- The largest Kyntra Bio buyer in Q2 2016 was Vanguard Group, an estimated $6.22M added.
- The largest Kyntra Bio seller in Q2 2016 was Visium Asset Management, an estimated $50.3M sold.
Based on aggregated 13F filings for Q2 2016.